APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors), Immunomodulators

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [7]

Active Indication

Myasthenia GravisRheumatoid ArthritisSystemic Lupus Erythematosus+ [10]

Inactive Indication-

Originator Organization

RemeGen Co., Ltd.

Active Organization

RemeGen Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (09 Mar 2021),

Systemic Lupus Erythematosus

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Conditional marketing approval (China), Priority Review (China)

Structure/Sequence

Sequence Code 616721115

Source: *****

Clinical Trials associated with Telitacicept

NCT07008196

/ Not yet recruitingPhase 4IIT

An Exploratory Clinical Study on Telitacicept for the Treatment of Refractory Rheumatoid Arthritis

This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.

Start Date10 Jun 2025

Sponsor / Collaborator

Chinese SLE Treatment And Research Group

NCT06827587

/ Not yet recruitingNot ApplicableIIT

Efficacy, Safety, and PKPD Study of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis (gMG): an Open-label, Randomized Controlled Trial

Title: The Efficacy, Safety, and PK/PD of Efgartigimod Followed by Telitacicept in Generalized Myasthenia Gravis: Protocol of a Randomized Controlled Trial Objective: This study aims to evaluate the efficacy, safety, and pharmacokinetics/pharmacodynamics (PK/PD) of efgartigimod followed by telitacicept in patients with generalized myasthenia gravis (gMG). Specifically, the trial seeks to determine the optimal treatment strategy for gMG by assessing the effect of sequential biologic therapy on disease management.
Study Design: This is a multi-center, open-label, randomized controlled trial involving 60 acetylcholine receptor antibody-positive gMG patients.

Start Date01 Feb 2025

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

[+3]

ChiCTR2500096335

/ SuspendedNot ApplicableIIT

A randomized controlled trial of Telitacicept in the treatment of IgA nephropathy after kidney transplantation

Start Date22 Jan 2025

Sponsor / Collaborator-

100 Clinical Results associated with Telitacicept

100 Translational Medicine associated with Telitacicept

100 Patents (Medical) associated with Telitacicept

113

Literatures (Medical) associated with Telitacicept

31 Dec 2025·RENAL FAILURE

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study

Article

Author: Qin, Wei ; Tan, Jiaxing ; Tang, Yi ; Wang, Siqing ; Qin, Aiya ; Yang, Dandan ; Dong, Lingqiu

BACKGROUND:

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.

AIM:

To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.

METHODS:

Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.

RESULTS:

Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.

CONCLUSION:

Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.

01 Jun 2025·CLINICAL RHEUMATOLOGY

Effects of telitacicept in SLE patients with antiphospholipid antibody positivity: a retrospective self-controlled case series

Article

Author: You, Yong ; Cai, Shaozhe ; Dong, Lingli ; Ye, Cong ; Zhou, Liling

OBJECTIVES:

Antiphospholipid antibody (aPL) is closely related to the manifestation of antiphospholipid syndrome (APS) and an increased risk of thrombosis in systemic lupus erythematosus (SLE) patients. Telitacicept is a new dual B cell inhibitor which has been approved in China to treat SLE, but its application in APS or aPL-positive patients is still lacking. This study aimed to observe the effects of telitacicept in SLE patients with aPL positivity.

METHODS:

It is a retrospective self-controlled case series study on SLE patients with aPL positivity who received telitacicept at a Chinese medical center during June 2021 to March 2023. Demographical information, clinical and immunological characteristics, and aPL profiles were gleaned from the electronic medical records system, and response of aPL profiles to telitacicept treatment was analyzed.

RESULTS:

Sixteen SLE patients were included. Eight of them were definite APS, and the other eight patients were aPL carriers. After 6 months of telitacicept administration, significant improvements were observed in parameters representing SLE disease activity, including SLEDAI-2 K, anti-dsDNA antibody levels, and complement levels. Meanwhile, we observed significant decreases in aPL levels that had not been previously reported. LAC normalized ratios significantly decreased from baseline after telitacicept treatment for 6 months (dRVVT: 1.86 (1.24, 2.80) vs. 1.44 (1.11, 1.94), P = 007; SCT: 1.76 (1.28, 3.23) vs. 1.36 (1.06, 2.01), P = 0.010). The titer of aCL IgG decreased from 196.6 (54.58, 328.85) to 90.20 (15.6, 202.20) CU, and anti-β2GPI IgG decreased from 828.70 (51.60, 2490.80) to 211.10 (18.40, 422.50) CU after 6 months of telitacicept treatment (P-value 0.005 and 0.013, respectively). Interestingly, a rebound tendency in aPL titers was observed after telitacicept withdrawal. No thrombosis events or pregnancy morbidities occurred, and no serious adverse events or death happened during treatment.

CONCLUSIONS:

Telitacicept may be an effective and safe option for patients with persistent aPL. Further well-designed prospective cohort studies are needed to confirm these findings. Key Points • Telitacicept is effective to lower aPL titers and promote aPL seroconversion, which may provide potential for the application of telitacicept in APS by reducing aPL-related events. • No thrombosis events and serious adverse events happened in aPL-positive patients during telitacicept treatment.

19 May 2025·ChemSusChem

Enhanced Charge and Energy Transfer in All‐Small‐Molecule Ternary Organic Solar Cells: Transient Photocurrent and Photovoltage and Transient Photoluminescence Measurements

Article

Author: Singhal, Rahul ; de la Cruz, Pilar ; Caballero, Rubén ; Sharma, Ganesh D. ; Langa, Fernando

Abstract:

A donor‐acceptor‐donor (D−A−D) molecule, denoted as RC18, consisting of two nickel‐porphyrin terminal donor units (D) and a selenophene‐flanked diketopyrrolopyrrole central core, connected via an ethynylene linker has been synthesized. The highest occupied molecular orbital and lowest unoccupied molecular orbital energy levels were measured showing values of −5.49 eV and −3.75 eV, respectively. We have utilized RC18 as donor along with two acceptors, DICTF and Y6, for OSCs and found that power conversion efficiencies were 12.10 % and 12.59 % for RC18:DICTF and RC18:Y6, respectively. The complementary absorption profiles of RC18, DICTF and Y6, along with the intermediate LUMO level of DICTF between RC18 and Y6, led to the fabrication of ternary organic solar cells. RC18:DICTF:Y6 based ternary attained power conversion efficiency of 16.06 %. The observed enhancement in the PCE is attributed to efficient exciton utilization through energy transfer from DICTF to Y6, increased donor‐acceptor interfacial area, suppressed charge carrier recombination and improved molecular ordering. These all factors contribute to improvements in short‐circuit current density (JSC) and fill factor (FF). Additionally, the open‐circuit voltage (VOC) of the ternary OSC lies between those of the two binary OSCs indicating the formation of an alloy between the two acceptors.

News (Medical) associated with Telitacicept

17 Jun 2025

·www.prnewswire.com

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of Myasthenia Gravis (MG), marking a key milestone achieved in its global development. Telitacicept now is the first dual-target biologic drug for MG with ODD from both FDA and EMA worldwide. The designation, granted based on telitacicept's significant benefits in treating the life-threatening rare disease of MG, will provide advantages to this novel agent on protocol assistance, regulatory fee reductions/waivers and up to 10 years of market exclusivity, thereby accelerating the clinical development, registration and drug approval process in Europe and its availability among MG patients. MG is an acquired antibody-mediated rare autoimmune disorder affecting the neuromuscular junction. According to the Myasthenia Gravis Foundation of America (MGFA) and various studies, its global prevalence is estimated to be 15-25 per 100,000, meeting EMA's definition of the rare disease (the prevalence of less than 5 in 10,000 in the EU). Though the current treatment options (including cholinesterase inhibitors, glucocorticoids, immunosuppressants, intravenous immunoglobulins, plasma exchange, and targeted biological agents) may help to manage symptoms, many patients still suffer from poor response, drug intolerance and disease relapse, highlighting a significant unmet clinical need. Telitacicept is the world's first approved innovative BLyS/APRIL dual-targeting fusion protein drug for MG. The pathology of MG is characterized by the autoantibodies produced by pathological B cells attacking the neuromuscular junction protein (such as acetylcholine receptor, muscle-specific tyrosine kinase). Telitacicept can block both BLyS and APRIL signaling pathways, effectively inhibiting abnormally activated B cells and reducing the production of pathogenic autoantibodies, which is expected to interfere with the source of disease progress of MG. Telitacicept was approved for marketing in China in May this year. Its phase III clinical trial boasts excellent results: after treatment with telitacicept for 24 weeks, improvement ≥ 3 points in myasthenia gravis-activities of daily living (MG-ADL) was observed in 98.1% of participants (12.0% in the placebo group) and improvements ≥ 5 points in quantitative myasthenia gravis (QMG) score was observed in 87% of participants (16.0% in the placebo group), with statistically significant difference in efficacy from the placebo group and manageable safety profile. The ODD granted by EMA represents the recognition of telitacicept's innovative mechanism of action and potential in treating MG. RemeGen is proceeding the global multi-center phase III clinical trial of telitacicept in patients with MG to bring the breakthrough treatment option to more patients globally. SOURCE RemeGen Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Orphan DrugDrug ApprovalImmunotherapy

27 May 2025

·www.prnewswire.com

RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China

YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in combination with conventional therapies. As the world's first innovative biologic drug targeting both BLyS and APRIL for the treatment of myasthenia gravis (MG), Telitacicept's approval not only brings new treatment options to patients, but also fills the gap of domestic innovative drugs in the field of MG treatment in China. It is expected to reshape the treatment landscape in this field. Previously, the indication of Telitacicept for MG was included in the breakthrough therapy category and priority review by the NMPA of China, and was granted orphan drug qualification and fast track designation by the FDA. Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment cycles and high recurrence rate. Approximately 80%-85% of patients with MG patients are AChR antibody positive, and more than 85% of patients develop to gMG within 24 months of onset. According to Frost & Sullivan report, there are about 1.2 million MG patients worldwide, including approximately 220,000 patients in China. At present, there is a great unmet medical need. Telitacicept is constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor and the fragment crystallizable (Fc) domain of human immunoglobulin G(IgG). It simultaneously targets B-cell lymphocyte stimulator (also known as BLyS) and a proliferation-inducing ligand (APRIL), and directly attack the source of pathenogenic antibody production – B cells and plasma cells. According to the phase III data presented at the annual meeting of the American Academy of Neurology (AAN) on April 9, 2025, Telitacicept demonstrated a clinically meaningful efficacy and safety profile in patients with gMG. According to the data, after 24 weeks of treatment, 98.1% of patients in the Telitacicept group demonstrated a ≥ 3-point improvement in Myasthenia Gravis Activities of Daily Living ("MG-ADL") score, far exceeding that of the placebo group which was 12.0%. The MG-ADL score decreased by 5.74 points from baseline in the Telitacicept group, compared to a decrease of 0.91 point in the placebo group. 87.0% of the patients in the Telitacicept group demonstrated a ≥ 5-point improvement in Quantitative Myasthenia Gravis ("QMG") score, far exceeding that of the placebo group which was 16.0%. The QMG score decreased by 8.66 points from baseline in the Telitacicept, compared to a decrease of 2.27 points in the placebo group, thereby proving significant treatment benefit. In terms of safety, the overall adverse event (AE) rate in the Telitacicept group was comparable to that in the placebo group, indicating a good overall safety profile. Among the drugs for gMG that have completed phase III clinical studies, Telitacicept had the highest MG-ADL response rate. The approval of Telitacicept in China will benefit more patients with MG in the country, thereby allowing more ambitious treatment goals to be achieved in terms of long-term disease management. Currently, the Company is advancing the global multi-center phase III trial of Telitacicept in patients with MG, aiming to validate the efficacy and safety of Telitacicept in a wider patient population. The principal researcher, Professor Yin Jian from Beijing Hospital, said: "We sincerely congratulate the approval of the therapeutic indication of Telitacicept for MG! Telitacicept demonstrated rapid and significant clinical improvements in the Phase III trial with good tolerability. This is a major breakthrough and key progress for Chinese innovative drugs in the field of neuro-immune diseases. It provides a high profile basis for evidence-based clinical application of Telitacicept in the treatment of MG, and has also opened up a new paradigm of precise treatment in this field. We believe that with the inclusion of this indication in the medical insurance, Telitacicept will bring new and more effective treatment options to more patients." Dr. Fang Jianmin, the CEO of RemeGen, said: "The approval of the MG indication for Telitacicept in China is of great significance. It provides clinicians with a new and more powerful 'weapon' to treat patients more effectively and precisely. We look forward to the inclusion of this indication in the medical insurance system to help patients and their families reduce the burden of treatment and further improve their quality of life. RemeGen is advancing the global Phase III clinical study of Telitacicept for MG. We are looking forward to working closely with global experts and scholars to contribute to the continuous advancement of treating autoimmune diseases." Aside from Myasthenia Gravis, Telitacicept has been approved in China for the treatment of two other major indications, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). SOURCE RemeGen Co., Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Clinical ResultOrphan DrugFast TrackDrug Approval

10 Apr 2025

·pipelinereview.com

Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱 ® ) in patients with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the American Academy of Neurology (AAN) Annual Meeting 2025 in San Diego, CA. According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score and 87% of the patients demonstrated a ≥ 5-point reduction in Quantitative Myasthenia Gravis (QMG) score at Week 24. With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG. Telitacicept is a novel fusion protein targeting both BlyS and APRIL independently designed and developed by RemeGen Co.,Ltd. (“RemeGen”). The multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial was conducted in China (NCT05737160) and led by Professor Jian Yin of Beijing Hospital. A total of 114 gMG patients with baseline MG-ADL score ≥6 and QMG score ≥8 were enrolled in the study, with 57 patients in the Telitacicept 240 mg group and the placebo group respectively. The study consisted of a 24-week double-blind treatment stage and an open-label treatment stage. The presented results herein were from the double-blind treatment study. The data showed that ‌Telitacicept‌ achieved ‌sustained and significant improvement‌ in clinical outcomes for patients with gMG, ‌with a favorable safety profile： The principal investigator Prof. Yin Jian of Beijing Hospital said “Telitacicept demonstrated rapid and significant clinical improvement in the phase 3 trial, and was well tolerated. Its dual-targeting mechanism not only inhibits abnormal B cells and plasma cells thoroughly and reduces the level of pathogenic antibodies, but also effectively slows down disease progression in the long term, and reduces steroid dosage as symptoms improve, providing a more precise, efficient, persistent, and safer option for gMG treatment.” Dr. Jianmin Fang, CEO of RemeGen, said “The phase 3 data of Telitacicept for MG is clinically meaningful. There is a large unmet medical need in MG because the disease presents significant threat to patients’ health and life-span. This breakthrough means that we have an new, effective treatment for MG as Telitacicept can significantly improve patients’ symptoms and bring long term benefits to MG patients. We look forward to working with global experts and scholars to overcome more complex autoimmune diseases and benefit more patients.” MG is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fatigue and fluctuations in symptoms, long treatment cycles and high recurrence rate. More than 85% of patients develop to gMG within 24 months of onset. According to Frost & Sullivan report, there are about 1.2 million MG patients worldwide, including about 220,000 patients in China. At present, there is a great unmet medical demand. The newly disclosed “best-in-class” data mark a breakthrough achievement of Chinese innovative drugs in the field of neuroimmunology. Currently, the BLA of Telitacicept for the treatment of gMG has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration, and it is expected to be approved in China in the second quarter of this year. Meanwhile, RemeGen is advancing a global multicenter Phase 3 trial of Telitacicept for the treatment of gMG, aiming to validate the efficacy and safety of Telitacicept in a wider patient population, and to provide a superior treatment option for gMG patients worldwide. SOURCE: RemeGen Co.

Phase 3Clinical Result

100 Deals associated with Telitacicept

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L04AA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myasthenia Gravis	China	RemeGen Co., Ltd.	20 May 2025
Rheumatoid Arthritis	China	RemeGen Co., Ltd.	16 Jul 2024
Systemic Lupus Erythematosus	China	RemeGen Co., Ltd.	09 Mar 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Sjögren's syndrome	Phase 3	China	RemeGen Co., Ltd.	03 Apr 2023
Lambert-Eaton Myasthenic Syndrome	Phase 3	China	RemeGen Co., Ltd.	28 Mar 2023
Glomerulonephritis, IGA	Phase 3	United States	RemeGen Co., Ltd.	18 Nov 2022
Neuromyelitis Optica	Phase 3	China	RemeGen Co., Ltd.	12 Jan 2018
Lupus Nephritis	Phase 2	China	RemeGen Co., Ltd.	17 Apr 2023
Multiple Sclerosis, Relapsing-Remitting	Phase 2	China	RemeGen Co., Ltd.	13 May 2021
Glomerulonephritis, Membranous	Phase 1	China	RemeGen Co., Ltd.	-
Interstitial lung disease due to connective tissue disease	IND Approval	China	RemeGen Co., Ltd.	19 May 2025
Nephrosis	IND Approval	China	RemeGen Co., Ltd.	22 Jul 2024
Immunoglobulin G4-Related Disease	IND Approval	China	RemeGen Co., Ltd.	17 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05737160 (PipelineReview) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	zbkyajfeyl(nburyyprew) = stymtmwfrf mplumozhyi (flsjxtqcsc ) View more	Positive	08 Apr 2025
				Placebo	zbkyajfeyl(nburyyprew) = iyhvzkjbtw mplumozhyi (flsjxtqcsc ) View more
NCT06456580 (RemeMG, AAN2025) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	jjnuawpduj(xlvfyafgpp) = qaterpvczc vfvqzpinuh (lbsfbafyvf ) View more	Positive	05 Apr 2025
				Placebo	jjnuawpduj(xlvfyafgpp) = kzobmrmtll vfvqzpinuh (lbsfbafyvf ) View more
NEWS Manual	Not Applicable	Glomerulonephritis, IGA	-	Telitacicept	hkphhdoour(ourxxdvuhi) = ilqztjmjxk uzushogjak (aezxsasmfe ) View more	Positive	15 Nov 2024
				Supportive treatment	hkphhdoour(ourxxdvuhi) = bsxmjjfgxn uzushogjak (aezxsasmfe ) View more
NCT02885610 (Pubmed \| Ann Rheum Dis) Manual	Phase 2	Systemic Lupus Erythematosus	249	Telitacicept 80 mg	jwrqriqunm(xnkudfdmde) = igexcdiiay dozxmrujqp (kjffynlaqz )	Positive	01 Apr 2024
				Telitacicept 160 mg	jwrqriqunm(xnkudfdmde) = kstsfzbsrz dozxmrujqp (kjffynlaqz )
NCT04078386 (Literature) Manual	Phase 2	Primary Sjögren's syndrome	42	telitacicept 160 mg	cncthhregz(oqaxnxgksb) = None hftbcnthxe (ijovnvreob ) View more	Positive	01 Mar 2024
				telitacicept 240 mg
NCT03016013 (ACR2023) Manual	Phase 3	Rheumatoid Arthritis	479	Telitacicept 160 mg	vwbivfwfik(zsdflalgad) = lpqldfclhz kwhakskvjr (varsjslbxc ) View more	Positive	24 Oct 2023
				Placebo	vwbivfwfik(zsdflalgad) = uecwmlsajk kwhakskvjr (varsjslbxc ) View more
NCT04078386 (Corporate Publications) Manual	Phase 2	Primary Sjögren's syndrome	42	placebo	wqnacrsauo(jrqbtmklqy) = jihivrzamo jasykutpxc (yxjpxetfbk, 4.55)	Positive	17 Jul 2023
				Telitacicept 160 mg	wqnacrsauo(jrqbtmklqy) = arcorgbslq jasykutpxc (yxjpxetfbk, 2.73)
EULAR2023	Phase 3	Systemic Lupus Erythematosus ANA/anti-dsDNA \| C3 \| C4 ... View more	335	Telitacicept 160 mg	msgewnwysm(skkbphbaxg) = glxgynwner xdmljyxety (qiidtwajim )	Positive	31 May 2023
				Placebo	msgewnwysm(skkbphbaxg) = rcwgjvcvuu xdmljyxety (qiidtwajim )
Pubmed Manual	Not Applicable	Systemic Lupus Erythematosus	20	Telitacicept	qydfximcmg(ftldzgqalg) = wlusiphdsg jqndvnnhef (jbcfzfrgdz ) View more	Positive	23 Nov 2022
NCT04302103 (Corporate Publications) Manual	Phase 2	Myasthenia Gravis	29	泰它西普 (160mg)	aeumlvzsat(ebifubgqpb) = pwyiskcetv kgdakgcwqq (crgsjkouwg )	Positive	31 Oct 2022
				泰它西普 (240mg)	aeumlvzsat(ebifubgqpb) = qkjbqqkxot kgdakgcwqq (crgsjkouwg )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis